Chief Scientific Officer
Patrick is the Chief Scientific Officer and a founder of Cullinan Oncology, as well as an Entrepreneur at MPM and BioImpact Capital. An immune oncology pioneer with extensive experience, Patrick has co-founded seven MPM oncology portfolio companies including Harpoon, TCR², iOmx, Maverick, Cullinan Oncology, Aktis Oncology and Werewolf.
Prior to founding Cullinan Oncology and becoming the Chief Scientific Officer, Patrick served as Vice President of Research and General Manager of Amgen Research Munich GmbH and as CSO for Micromet. He earlier headed small-molecule drug discovery at Tularik, a publicly traded biotechnology company acquired by Amgen. Prior to this, he was Professor and Chairman of Biochemistry and Molecular Biology at the Medical Faculty of Freiburg University, Germany, where he did groundbreaking research on transcription factor NF-kappaB.
Patrick holds a Ph.D. in Biology from the University of Munich (LMU) and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty of LMU in Munich, Germany and is an elected member of the German National Academy of Sciences Leopoldina.
Chief Medical Officer
Dr. Jeffrey Jones has over 15 years of clinical development experience in academia and industry, with skills ranging from clinical trials, drug development, medical education, and healthcare management. Previously, Dr. Jones served as Vice President, Global Drug Development, Lymphoma and Myeloid Diseases at Bristol-Myers Squibb, where he led the development and lifecycle management strategy for Reblozyl®. Earlier, Dr. Jones was Clinical Strategy Lead for Lymphoma and Chronic Lymphocytic Leukemia, Global Clinical Research and Development at Celgene, where he shaped clinical and business development strategy across a diverse portfolio of small and large molecules in early- through late-stage development.
Before joining the industry in 2017, Dr. Jones was Associate Professor of Internal Medicine in the Division of Hematology at The Ohio State University. While at Ohio State, Dr. Jones led the Chronic Lymphocytic Leukemia clinical research program and represented the Division of Hematology as Clinical Research Leader in the OSU Comprehensive Cancer Center. Dr. Jones holds an M.B.A. from The Ohio State University Fisher College of Business, an M.P.H. from the University of Texas School of Public Health and an M.D. from the University of Michigan Medical School, completing his residency in internal medicine at McGill University.
Chief Development Officer
Jennifer is a skilled scientific leader with 17+ years of experience in oncology, immunology, and immune-oncology. Prior to joining Cullinan Oncology, Jennifer served as Senior Director and Executive Program Leader at Jounce Therapeutics, where she led the flagship ICOS antibody program, JTX-2011, from inception into Phase 2 development. An employee since company launch and serving on its leadership team, Jennifer built and led multiple departments at Jounce, including Tumor Immunology, Pharmacology, and Preclinical Development.
Previously, during her 10-year tenure at Biogen, Jennifer served as project leader for several monoclonal antibody and bispecific antibody programs in both the oncology and immunology therapeutic areas. Jennifer has also worked as a consultant at Third Rock Ventures for multiple stealth companies.
Jennifer received her B.A. in Biology from Princeton University and Ph.D. from the Department of Cell Biology at Albert Einstein College of Medicine and completed a post-doctoral fellowship in Philip Leder’s laboratory in the Department of Genetics at Harvard Medical School.
Chief Business Officer
Corinne is highly accomplished in pharmaceutical research and development, oncology and international business development. Prior to joining Cullinan Oncology, Corinne served as Global Head, Business Development and Licensing for Novartis Pharma. In this role, Corinne oversaw the execution and management of over 20 major transactions across multiple therapeutic areas including in-licensing, option and equity deals, spin-outs, and divestments. Corinne started her career as a researcher at AstraZeneca and Imutran, a UK-based biotech company, where she was Research Director. Novartis acquired Imutran in 1996 and Corinne was promoted to CEO of Imutran. Since 2001, Corinne continued to hold increasingly senior leadership positions within Novartis. She was the European Head of the Transplant and Immunology Business, the Global Head Search and Evaluation for Business Development and prior to her last role the Global Head of Pricing and Market Access where she was responsible for the price and access strategies for the entire Novartis portfolio.
Corinne received a B.S. in Biochemistry from the University of Manchester (UK) and conducted her postgraduate research at University College and Middlesex School of Medicine (Ph.D.) and the Charing Cross Sunley Research Centre in London.
Chief Financial Officer
Senior Vice President, Communications
Rose is an expert communications professional in the pharmaceutical and biotech industries. Prior to joining Cullinan Oncology, she held roles of increasing responsibility in Corporate Affairs at Bristol Myers Squibb, with leadership positions in Science and Commercial Communications, Global Hematology, and Corporate Communications. Rose joined Bristol Myers Squibb after leading communications for the U.S. site for Otsuka. Previously, Rose held business communications roles at Sanofi. Rose earned her Master’s degree in Finance from La Salle University in Philadelphia.
President and Chief Executive Officer
Nadim has more than twenty-five years of leadership experience in oncology across a range of development and commercialization roles, including recently at Bristol Myers Squibb (BMS), where he served as President, Hematology and at Celgene Corporation (Celgene) where he served as President, Global Hematology & Oncology. As President, Hematology at BMS, Nadim oversaw multiple product launches and served as a member of the company’s Leadership Team. Prior to BMS, Nadim served in leadership roles at Celgene across both development and commercialization functions. Nadim has expertise in various treatment modalities, including small molecules, biologics, and cell therapy in hematology and solid tumors. Nadim holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.
Nadim currently serves on the Board of Directors for Family Promise, a national non-profit organization helping families impacted by homelessness.